Compare Etsy Inc (ETSY) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Etsy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Etsy Inc trades at $85.51 (market cap $8.14B), while Vertex Pharmaceuticals Incorporated trades at $477.12 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 14.9× Etsy Inc's market cap, and Etsy Inc is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals.
| ETSY | VRTX | |
|---|---|---|
Market Cap | $8.14B | $121.09B |
Sector | Consumer Cyclical | Health |
52-Week High | $85.74 | $529.59 |
52-Week Low | $44.05 | $366.54 |
Enterprise Value | $9.79B | $115.83B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ETSY trades at $84.30, up 1.49% today, with a bullish technical signal from moving averages. The stock shows strong earnings beats in recent quarters but faces declining revenue and net income margins year-over-year. Positive sentiment is driven by AI-powered seller tools and app engagement growth, though active buyer declines remain a concern. Cash flow improved significantly in 2025 to $593 million.
Outlook is mixed: analyst consensus is cautious with a $72.38 price target below current levels, but technical momentum and AI initiatives offer upside potential. Key risks include high debt, competitive pressure, and inconsistent profitability. Institutional sentiment leans bullish with 49% buy ratings.
Vertex Pharmaceuticals (VRTX) trades at $481.35, up 1.06% today, and is near its 52-week high. The stock shows a bullish technical signal with support at $471 and resistance at $482. Fundamentally, the company reported strong 2025 results with $12.0B revenue and $4.0B net income, though 2024 saw a loss. The recent $10B acquisition of Crinetics Pharmaceuticals aims to expand its endocrinology pipeline, potentially adding $5B in peak sales.
Outlook remains positive with analyst consensus at 'Buy' and a $538 price target, implying 12% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments. Earnings growth and pipeline expansion are primary catalysts, but investors should monitor execution on acquisitions and competitive pressures in biotech.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
